China Pharmahub (OTC BB:CPHB)

China PharmaHub Corp enters U.S. public market: Revere merger is expected to close on August 10, 2010.

Company Snapshot:

PharmaHub’s business is the identification, licensing, development and commercialization of pharmaceutical and healthcare products and technologies between the People’s Republic of China (“PRC”) and the rest of the world. (Please note that the company is less than a year old)

Industry Snapshot:

• The biotech market has experienced challenges with large pharmaceutical companies having patent expirations, increased costs and risks of developing new drugs and the lack of a promising new drug pipeline. Small biotech companies have faced limited funding resources, especially in light of the difficulties currently experienced by the capital markets.
  
• In recent years, the pharmaceutical market in the PRC has grown at a CAGR of 27% from 2006 to 2009. This represents a 13% faster growth rate than initially expected, according to IMS Health Incorporated, a company specializing in pharmaceutical market intelligence.
  
• The pharmaceutical market is predicted to drive $40 billion in growth over the next 3 to 4 years.
  
• With a massive population of over 1.3 billion people, and a focus on healthcare improvement with a $125 billion investment by the government, the PRC’s pharmaceutical market is expected to double by 2013. The PRC has a vast pharmaceutical market and its research and development facilities have become world-class.

Post Merger Share Calculation:

•   6,478,559: Pre reverse merger outstanding shares
• 13,766,983: Newly issued shares of Common Stock
•   1,478,559: Shares held in escrow

GeoTeam® best effort calculation of total post reverse merger shares assuming full conversions:  21,724,101

Financial Snapshot: TBA